G-CSF/IgG1-FcL also proved significantly more potent than G-CSF at accelerating recovery from neutropenia in CPA-treated rats, which is a model for chemotherapy-induced neutropenia in cancer patients, the largest clinical indication for G-CSF. This evidence concerns the gene CSF3 and cancer.